EyePoint Pharmaceuticals, Inc.

Stock ticker:

After the market had closed on August 30, 2022, EyePoint Pharmaceuticals, Inc. disclosed that the company received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts seeking documents related to sales practices for its postoperative inflammation treatment, DEXYCU.

Shares of EyePoint Pharmaceuticals, Inc. fell more than 20% in after-hours trading on August 30, 2022, following the disclosure.

Download Complaint

Are you a victim of corporate fraud?

Talk to us about your case.

Contact our attorneys for a no-cost case evaluation.